Free CME's

Introduction to Infant Cardio-Pulmonary Resuscitation (CPR) is organized by University Health Care System and will be held on May 23, 2019 at University Hospital, Augusta, Georgia, United States of America. Course Description: Do you worry about knowing how to revive your baby should the need arise? This FREE class provides you with an opportunity to learn and practice infant CPR on our mannequins and also learn other aspects of infant safety. • Upon arrival at University Hospital, come into the main entrance • Please be seated in the large lounge area • The instructor will come to greet everyone and lead you to the classroom Additional details will be posted as soon as they are available.

MEDITECH 2019: The Medical and Health-Care Device Development Leading Conference is organized by New-Tech Magazines Ltd and will be held from May 28 - 29, 2019 at The israel trade Fairs center in Tel Aviv, Yafo, Tel Aviv, Israel. The subjects dealt with at the conference will include the development of medical instrumentation, components for medical devices, test equipment for medical equipment and instrumentation, the miniaturization of medical devices, the development of special non-intrusive instrumentation and procedures, medical device production standards, medical equipment packaging, the use of laser and electro-optics devices in medical instrumentation, sensors, cables, connectors, computer embedded systems, industrial automation, power supply etc. The conference is targeted at developers in the medical engineering industry, manufacturers of medicalinstrumentation, medical instrumentation start-ups, academy representatives, medical venture capital companies and investors, hospital maintenance companies, medical instrumentation operators, medical laboratory managers and medical hothouse companies. Additional details will be posted as soon as they are available.

ROBOTICS 2019: The Annual Robotics & Automation Conference is organized by New-Tech Magazines Ltd and will be held from May 29 - 30, 2019 at The israel trade Fairs center in Tel Aviv, Yafo, Tel Aviv, Israel. The conference will exhibit innovations and achievements of the industry and the academia in the field of robotics and automation. The conference program will include a range of lectures of the best lecturers of the industry and academia. The conference includes lectures from the medical, defense, industrial, autonomous vehicle and other fields. Alongside the conference is an extensive display of leading control and robotics companies. Participation in the conference is free of charge but advanced registration and the organizing company’s approval are required. The conference and exhibition are for employees of high-tech and electronic industries, academic institutions and the security forces. Additional details will be posted as soon as they are available.

Strategies to Maximize the Clinical Benefit of EGFR TKIs in Advanced NSCLC (May 2019) is organized by Clinical Care Options (CCO), LLC and will be held on May 31, 2019 at Sheraton Grand Chicago, Chicago, Illinois, United States of America. Target Audience: This program is intended for physicians, oncology nurses, pharmacists, and other healthcare providers who care for patients with non-small-cell lung cancer. Accreditation: Physician Continuing Medical Education: The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nursing Continuing Education: The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours. Pharmacist Continuing Education: Credit Designation: Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hours (0.2 CEUs) of the Accreditation Council for Pharmacy Education. Goal Statement: The goal of this activity is to improve participants’ knowledge of and competence in applying EGFR inhibitors in the treatment of patients with EGFR-mutated non-small-cell lung cancer. Learning Objectives: • Apply expert recommendations for frontline therapy for advanced EGFR-mutated NSCLC focusing on safety, efficacy, and the individualization of therapy based on tumor-specific and patient-specific factors • Compare the efficacy and safety of first-generation EGFR TKIs with later-generation EGFR TKIs • Examine current recommendations for molecular testing and the roles for liquid biopsies in guiding the use of EGFR TKI therapy • Plan optimal sequencing of EGFR TKIs after considering the available evidence and expert recommendations • Evaluate current and evolving treatment approaches to address acquired resistance and progression in advanced EGFR-mutated NSCLC

An Evening With Experts: Selecting and Sequencing Therapy in HR+/HER2- Metastatic Breast Cancer is organized by Clinical Care Options (CCO), LLC and will be held on May 31, 2019 at Sheraton Grand Chicago, Chicago, Illinois, United States of America. This CME Conference has been approved for a maximum of 2.00 AMA PRA Category 1 Credits™. Target Audience: This program is intended for oncologists and other allied healthcare professionals caring for patients with metastatic breast cancer receiving targeted therapy. Goal Statement: The goal of this activity is to improve the knowledge, confidence, and competence of oncology specialists and other clinicians caring for their patients with MBC receiving CDK4/6 inhibitors, mTOR inhibitors, PI3K inhibitors, and promising investigational agents. Learning Objectives: • Evaluate current guidelines and current/emerging clinical trial data on everolimus, palbociclib, palbociclib, and abemaciclib (in addition to others under clinical investigation) to aid in the refinement of current treatment algorithms for patients with de novo or recurrent HR-positive/HER2-negative MBC • Describe current therapeutic strategies and ongoing clinical trials of targeted therapy–based combinations for both early-stage and HR-positive, HER2-negative MBC • Identify ongoing trials investigating novel treatment options after disease progression on endocrine and/or CDK4/6 inhibitor-based therapy to aid in clinical trial participation  Additional details will be posted as soon as they are available.

Current Challenges and New Opportunities in Hematopoietic Stem Cell Transplant is Course organized by i3 Health and will be held from May 31 - Dec 31, 2019. Target Audience: Hematology/oncology physicians, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients eligible for HSCT. CreditS: 1.0 AMA PRA Category 1 Credit ™ 1.0 contact hour Description: Hematopoietic stem cell transplant is a potentially curative therapy for patients with hematologic malignancies. There are 2 primary types of HSCT: autologous, where the cells are taken from the patient, and allogeneic, where the cells come from a matched sibling donor or an unrelated donor. Advances in HSCT include the introduction of reduced-intensity conditioning regimens that allow transplant in older patients and alternative graft sources that afford a donor for nearly all patients who require a transplant. Despite these advances, studies continue to show that the use of HSCT remains suboptimal, placing many patients at increased risk for poor survival outcomes. Objectives: Upon completion of this activity, participants should be able to: • Assess the susceptibility of hematologic malignancies to the graft-versus-leukemia effects of HSCT • Evaluate emerging data on conditioning and consolidation/maintenance therapies that can optimize HSCT outcomes • Apply strategies to manage transplant-related complications so that patients may achieve their goals of cancer therapy.

B-Cell Malignancies - Expert Guidance on BTK Inhibitors for Today’s Clinic is organized by Clinical Care Options (CCO), LLC and will be held on Jun 01, 2019 at Sheraton Grand Chicago, Chicago, Illinois, United States of America. This CME Conference has been approved for a maximum of 2.00 AMA PRA Category 1 Credits™. Target Audience  This program is intended for hematologists, hematologist-oncologists, and other clinicians involved in the management of patients with MCL, CLL, and other B-cell malignancies. Goal Statement The goal of this activity is to improve participants’ competence in using BTK inhibitors to improve treatment outcomes for patients with B-cell malignancies. Learning Objectives  • Evaluate differences among agents targeting BTK in terms of molecular characteristics, preclinical data, approved indications, dosing, safety profile, and efficacy • Consider existing and emerging clinical research data evaluating currently available and emerging BTK inhibitors (and BTK-based combinations) in the formulation of therapeutic recommendations for patients with MCL, CLL, and other B-cell malignancies • Recognize and manage adverse events and toxicities associated with BTK inhibitor therapy to support quality of life and continuation of treatment • Explain to patients the importance of and provide strategies for optimal adherence to prescribed BTK inhibitors • Assess ongoing clinical trials evaluating currently available and emerging BTK inhibitors (and BTK-based combinations) to aid clinical trial enrollment and predict new options in the clinic  Additional details will be posted as soon as they are available.

PARP Inhibitors in Breast Cancer: Expert Perspectives on Clinical Application and Genetic Testing is organized by Clinical Care Options (CCO), LLC and will be held on Jun 01, 2019 at Radisson Blu Aqua Hotel, Chicago, Chicago, Illinois, United States of America. Target Audience: This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with metastatic breast cancer. Accreditation: Physicians: NCCN designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses: NCCN designates this educational activity for a maximum of 2.0 contact hours. Pharmacists: NCCN designates this knowledge-based continuing education activity for 2.0 contact hours (0.2 CEUs) of continuing education credit. Goal Statement: The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in integrating PARP inhibitors into treatment of patients with breast cancer. Learning Objectives: • Describe the mechanism of action of the different PARP inhibitors and the rationale for PARP inhibition in treating metastatic breast cancer • Identify patients based on molecular changes and previous therapy that are most likely to benefit from treatments with PARP inhibitors • Integrate single-agent PARP inhibitors into the treatment of appropriately selected patients with metastatic breast cancer •Refer eligible patients with metastatic breast cancer to clinical trials of single-agent PARP inhibitors and combinations of PARP inhibitors with other anticancer therapies  Additional details will be posted as soon as they are available.

USF Health Vascular Surgery Fellows Finishing School is organized by USF Health’s Office of Continuing Professional Development (OCPD) and will be held from Jun 02 - 04, 2019 at USF Health, CAMLS, Tampa, Florida, United States of America. Target Audience: Vascular surgery fellows and fifth-year vascular surgery residents need only apply. Must provide proof of fellowship and residency from your institution. Activity Description: The Vascular Surgery Fellows Finishing School is a continuation of the Houston Methodist Course, which aims to provide a unique educational opportunity for vascular surgery graduating fellows and fifth year integrated vascular residents. This two-day course is designed to equip these fellows and resident with the tools they need to hone in on their skills in advanced open and endovascular techniques as well as focus on uncommon and complex procedures. Additionally, the opportunity to sharpen their cognitive and technical skills in complex peripheral and endovascular techniques. Prerequisites: Must provide proof of fellowship or residency from your institution. Additional details will be posted as soon as they are available.

Collaborative Strategies to Ensure Optimal Application of the Latest Treatment Approaches in HCC is organized by Clinical Care Options (CCO), LLC and will be held on Jun 02, 2019 at Radisson Blu Aqua Hotel, Chicago, Chicago, Illinois, United States of America. Target Audience: This program is intended for physicians, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare providers who care for patients with HCC. Accreditation: NCCN designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses: NCCN designates this educational activity for a maximum of 2.0 contact hours. Pharmacists: NCCN designates this knowledge-based continuing education activity for 2.0 contact hours (0.2 CEUs) of continuing education credit. Goal Statement: The goal of this activity is to improve participants’ competence in applying the latest treatment approaches and interdisciplinary collaborative strategies towards optimal care of patients with HCC. Learning Objectives: • Explore first-line treatment options for individual patients with advanced HCC, considering the available clinical evidence, known agent toxicity/ tolerability profiles, expert recommendations, and patient preferences • Apply clinical evidence and expert recommendations to select optimal treatment for patients with HCC        that has progressed on or after 1 or multiple lines of therapy • Plan therapeutic strategies that optimize the sequence of therapies to provide the best outcome to patients      with HCC • Counsel patients to help them understand their treatment options and to be proactive, knowledgeable            participants in their care • Employ effective collaborative strategies to ensure the best possible application of the latest HCC                  treatment approaches • Become familiar with the design of ongoing clinical trials for novel HCC treatment strategies, and counsel    appropriate patients about availability and participation